علاج التهاب رئة كوفيد-19 الخفيف إلى المتوسط في المرضى الخارجيين المعرضين لخطر مرتفع للتطور إلى مرض شديد

References

DOI: 10.1093/cid/ciac724

In ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within 5 days of symptom onset rather than no nirmatrelvir/ritonavir.

Mild-to-moderate illness is defined as patient with SpO2 >94% not requiring supplemental oxygen.

In ambulatory patients (≥18 years) with mild-to-moderate COVID-19 at high risk for progression to severe disease who have no other treatment options, the IDSA guideline panel suggests molnupiravir initiated within 5 days of symptom onset rather than no molnupiravir.

Molnupiravir 800 mg for 5 days.

If other treatment options are not available then consider molnupiravir for 5 days (oral) or, if immunocompromised, high-titer convalescent plasma (intravenous) with activity against circulating variant.